Key findings

  • 11 of 53countries in the WHO European Region have a β-thalassaemia carrier frequency of >2% in the indigenous population and are regarded as high-prevalence countries
  • Five of 11high-prevalence countries (Bulgaria, Cyprus, Greece, Italy and Malta) have services of high quality, based on outcome measures, particularly survival
  • 26,000patients with β-thalassaemia syndromes at least, and approximately 72,000 with SCD, across the 53 European countries, by rough estimates that are probably underestimates
  • 42.3 yearsmean age of patients with β-thalassaemia in Cyprus, where only 72 of 652 patients (11%) are aged <18 years

Abstract

Background
Haemoglobin disorders in Europe are common in countries along the Mediterranean coast but are also increasing in historically low-prevalence areas of northern and western Europe as a result of increasing migration. Service needs, encompassing both prevention and clinical management, are complex and require further improvement based on patient outcomes, both in high-prevalence countries and, particularly, in countries where these disorders have been introduced more recently.
Methods
We performed a multi-source study investigating prevention and clinical services focused on 28 countries across Europe.
Results
Of the 53 countries within the WHO Regional Office for Europe, 11 have a β-thalassaemia carrier frequency of >2% in the indigenous population and are therefore regarded as high-prevalence countries. Three are considered low-prevalence countries but have experienced a substantial and long-established impact of migrations from high-prevalence regions, while another 14 are considered low prevalence but show increasing trends due to more recent migrations. For the remaining 25 countries, information is largely unavailable. Epidemiological data remain incomplete in most countries because of the lack of reliable studies on carrier frequency and birth prevalence, as well as the limited availability of patient registries. Prevention programmes are best developed in high-prevalence countries and are based predominantly on premarital or preconception screening. Antenatal screening is practiced in countries where migration has resulted in increasing carrier rates, while in much of the rest of Europe there are no centrally supported programmes. Clinical management benefits from robust healthcare infrastructure in high-income countries, including adequate and safe blood transfusion services, access to medicines, and the availability of expert centres.
Conclusions
Based on clinical outcomes, with the exception of a few high-prevalence countries or those with long-standing experience in managing haemoglobin disorders, many patients face challenges related to the rarity of these conditions and the limited expertise in the multidisciplinary care required to achieve long-term survival and good quality of life. Prevention programmes also remain insufficiently developed or implemented in most countries. Policy actions are therefore needed to address these gaps and improve both prevention and clinical care.

Introduction

Haemoglobin disorders, mainly sickle cell disease (SCD) and β-thalassaemia, are the most common inherited blood disorders globally. Underdiagnosis (or delayed diagnosis) and underreporting, especially due to the lack of national registries, result in limited epidemiologic data and a probable underestimate of the real burden that these conditions impose on health services, families, and patients.1–3 SCD and β-thalassaemia are autosomal recessive disorders caused by mutations in the HBB gene on chromosome 11, which encodes β-globin; in β-thalassaemia, homozygous or compound heterozygous inheritance of mutations leads to reduced β-globin production, while in SCD, structural alteration of β-globin results in haemoglobin S, which polymerizes upon deoxygenation, causing red blood cell sickling. The basic pathophysiology of β-thalassemia is ineffective erythropoiesis, leading to chronic anaemia and abnormal iron metabolism (overload) due to increased iron absorption (non-transfusion-dependent β-thalassaemia, NTDT) or regular red-cell transfusions (transfusion-dependent β-thalassaemia, TDT), which affects vital organs, interfering with the function of the heart, liver, and endocrine glands.4 SCD also presents with complex pathophysiology involving vaso-occlusion, haemolysis, and inflammation that lead to acute, life-threatening complications and progressive organ damage.5

Both β-thalassaemia and SCD have, in well supported, robust healthcare systems evolved from childhood lethal conditions to chronic conditions of adulthood. Survival of β-thalassaemia patients in these settings is increasing and described as a ‘movement toward an elderly patient population’ with increasing comorbidities requiring multi-disciplinary care.6,7 In Cyprus, the mean age of patients with β-thalassaemia was around 42 years (median 44 years) in a 2022 report.8 Similar results have also been reported from Greek and Italian patient registries.6,7

High allele frequencies for sickle cell are encountered across most of sub-Saharan Africa, the Middle East, and India.9,10 β-Thalassaemia has a high prevalence in countries ranging from the Mediterranean basin, throughout the Middle East, the Indian sub-continent, South-East Asia, Melanesia, and the Pacific Islands.10–12 In many other European countries, especially of western and northern Europe, haemoglobinopathy genes are rare in the indigenous population. However, migrations from high prevalence regions of the world are affecting prevalence in Europe and lead to an increasing burden of these disorders.12–15 Prolonged survival is also contributing to the increasing prevalence in Europe.

The burden of haemoglobin disorders is determined not only by their prevalence, but also by the capacity of healthcare systems to provide timely diagnosis, prevention, and comprehensive lifelong care. Optimal outcomes require coordinated services spanning screening and genetic counselling, specialist clinical care, access to appropriate transfusion and iron chelation programmes, disease-modifying therapies, management of acute and chronic complications, and, where available, curative approaches. Consequently, substantial differences in healthcare infrastructure, resources, expertise, and access to treatment may translate into marked disparities in morbidity and survival between and within countries.

The aim of this study was to assess and describe the current status of prevention and clinical services for haemoglobin disorders across high-prevalence and selected low-prevalence countries in Europe, drawing on multiple data sources of varying completeness and reliability. We specifically explored disparities in the quality of services between various countries as evident keys from outcomes relevant to survival potential. The ultimate aim of this work is to promote service optimisation in view of the increasing prevalence of these disorders. Economic, social, and health system development varies across countries, and the policies adopted are therefore expected to differ accordingly.

Methods

We conducted a cross-sectional, multi-source study of prevention and clinical services for haemoglobin disorders across different countries in Europe listed under the World Health Organization (WHO) Regional Office. Only β-thalassaemia and SCD were considered, since data on α-thalassaemia in Europe is largely lacking. Countries were first categorised based on prevalence of β-thalassaemia: 1) high-prevalence countries – defined as having a carrier rate >2% in the indigenous population (n = 11); 2) low-prevalence countries – defined as having a carrier rate of <1%, but with established past and recent migrations from high-prevalence regions (n = 3); 3) low-prevalence countries with increasing recent migration trends (n = 14); and 4) unknown-prevalence or low-prevalence countries not affected by past or recent migration trends from high-prevalence regions (n = 25). Countries selected for this study were primarily those in the first three categories (Figure 1), considering that information from the fourth category is largely lacking. The report did not involve the collection or analysis of individual-level patient data and therefore did not require ethical review.

Figure 1. European countries considered in this report based on carrier frequency for β-thalassaemia. Figure created with assistance from ChatGPT (OpenAI, San Francisco, CA, USA) and subsequently reviewed and edited by the authors.

Data sources

A structured literature review was conducted using PubMed and Google Scholar for studies and reports describing services for haemoglobin disorders published between January 2006 and July 2026 (some key historical references were also included). Search terms used included ‘thalassaemia’, ‘sickle cell’, ‘carrier’, ‘frequency’, ‘prevention’, ‘screening’, ‘registry’, ‘blood transfusion’, ‘iron chelation’, and ‘cost of treatment’. These were searched alongside the general term ‘Europe’ or ‘European’ as well as individual country names. The search was limited to English literature.

In addition, we also retrieved essential information from the Thalassaemia International Federation (TIF) 2025 Global Thalassaemia Review16, unpublished reports of national thalassaemia associations communicated to TIF, and TIF delegation visits to relevant countries. Finally, we also included key insights from TIF’s network of healthcare professionals, mainly haematologists, in each country.

Expected affected births per year were calculated from the carrier rates based on the Hardy-Weinberg rule. The numbers of immigrants from high-prevalence regions were derived from Wikipedia (available at: https://en.wikipedia.org), Statista (available at: https://www.statista.com), or national datasets – all accessed during July 2026. For immigrants, the number of carriers was calculated based on the carrier rate of the country of origin. The following data sources were also accessed for national population and health economics metrics:

  • Total population and life expectancy at birth (2026 mid-year population estimates): United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2024. Available at: https://population.un.org/wpp/ (accessed July 2026).
  • Gross domestic product (GDP) (2026): · International Monetary Fund (IMF). World Economic Outlook Database, April 2026. Available at: https://data.imf.org/Datasets/WEO (accessed July 2026).
  • Human development index (HDI) (2023): United Nations Development Programme (UNDP). Human Development Index (HDI) Database. Available at: https://hdr.undp.org/data-center/human-development-index (accessed July 2026). It reflects achievement in key dimensions of human development including health (life expectancy at birth), education (years of schooling), and standard of living (gross national income per capita). The measure assesses development of services for the people and not economic growth alone.
  • World Bank rank (2026): World Bank. World Bank country and lending groups. Washington (DC): World Bank; 2026. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed July 2026). With classifications of high-income country (HIC), lower middle-income country (LMIC), and upper middle-income country (UMIC).
  • Health expenditure (2023): World Health Organization (WHO). Global Health Expenditure Database. Geneva: WHO; 2024. Available at: https://apps.who.int/nha/database (accessed July 2026).
  • Universal health coverage (UHC) (2023): World Health Organization (WHO). Universal health coverage (UHC) service coverage index (SDG 3.8.1). Geneva: WHO; 2024. Available at: https://data.who.int/indicators/i/3805B1E/9A706FD (accessed July 2026).

Where available, we also specifically searched for key indicators of service quality such as mean patients age, pretransfusion haemoglobin level, iron indices especially by magnetic resonance imaging (MRI), and national registry availability.

Results

Across Europe, the epidemiology and organisation of services for haemoglobin disorders showed substantial heterogeneity, broadly reflecting differences in underlying prevalence, historical and recent migration patterns, and healthcare system capacity. The findings are therefore presented according to three main settings: countries with traditionally high prevalence of haemoglobin disorders; low-prevalence countries with long-established migration from high-prevalence regions; and low-prevalence countries experiencing more recent increases in migration. Across these settings, important differences were observed in the availability of epidemiological data and registries, prevention programmes, specialist expertise, and organisation of clinical care.

High-prevalence countries

Eleven countries have been identified as high prevalence based on the pre-defined criteria, where β-thalassaemia is mainly regarded as a public health concern. Table 1 summarises basic epidemiologic data, while Table 2 summarises the general healthcare picture in these countries.

Table 1. Basic epidemiological data from high-prevalence European countries.

Countryβ-thal
carriers (%)
Expected β-thal
births/1000 LB
HbS
carriers (%)
Expected SCD
births/1000 LB
Estimated β-thal
patients/100,000
population
Estimated SCD
patients/100,000
population
Albania50.6251.40.39910.67.6
Azerbaijan3.70.3440.80.16412.91.9
Bulgaria2.50.1560.08040
Cyprus144.900.270.191596.5
Greece81.6400.60.2523011
Italy4.30.4622.10.56212.213.5
Malta30.2250.180.0285.20.7
North Macedonia2.60.169NA01.4NA
Tajikistan50.625NA0NANA
Türkiye2.20.1210.440.0536.250.9
Uzbekistan30.253NA01.32NA

Abbreviations: β-thal, β-thalassaemia; SCD, sickle cell disease (including HbSS and HbS/β-thalassaemia); LB, live annual births); NA, data not available.

Table 2. Overview of the general healthcare picture in high-prevalence European countries.

CountryTotal
population
Life
expectancy
at birth
WB RankGDP/capita
1000$
HE/capita $UHC indexHDI rank
Albania2,751,02580.13UMIC12.49590.63710.810 v high
Azerbaijan10,445,85574.89UMIC7.47299.81670.789 high
Bulgaria6,667,65976.13HIC23.851257.88730.845 v high
Cyprus1,382,33482.15HIC45.412899.36760.913 v high
Greece9,897,11582.39HIC29.71962.60770.908 v high
Italy58,926,16684.18HIC46.513397.69820.915 v high
Malta549,01183.78HIC53.563623.46820.924 v high
North Macedonia1,804,06377.81UMIC11.97639.42690.815 v high
Tajikistan10,978,59972.19LMIC1.9485.15720.691 med
Türkiye87,926,08278.38UMIC19.02547.81770.853 v high
Uzbekistan37,724,22372.78LMIC4.66192.12790.740 high
Total229,061,132

Abbreviations: WB, world bank; GDP, gross domestic product; HE, health expenditure; UHC, universal health coverage; HDI, human development index; HIC, high-income country; LMIC, lower middle-income country; UMIC, upper middle-income country (UMIC).

The prevalence of β-thalassaemia in these countries falls below the EU definition of rare disease (5 in 10,000 people), with the exception of Cyprus. SCD is also rare. Most countries have recognised the public health importance of β-thalassaemia and each has a policy, although not always comprehensive, to respond to the issues raised by patient needs. These responses vary with the health system and its potential to prioritise haemoglobin disorders.

Compared to other regions of the world, most of these countries perform well economically and in health service development. Three countries, however, lag behind in both health spending and universal coverage and these are reflected in lower life expectancy in the general population and in HDI ranking compared to the remaining eight countries: these are Azerbaijan, Tajikistan, and Uzbekistan. The last two have the least contact with TIF and the least data on haemoglobin disorders.

Albania. Albania is a southern European country in the Balkan Peninsula, with just under three million people. It is classified as an UMIC with significant economic growth in recent years.

Epidemiology: Haemoglobin disorders are more common on the Adriatic coast. According to the most recent figures from the patients’ association, there are a total of 530 patients with haemoglobin disorders, 356 with β-thalassaemia and 174 with SCD patients.17

Prevention: There is no national programme for prevention, so second and subsequent affected child prevention is practiced after a first affected child is born. Public awareness is low.

Clinical services: The blood transfusion service is coordinated by the National Blood Transfusion Center (NBTC) in Tirana, which operates under the Ministry of Health.18 There is a chronic shortage since blood donations in Albania are very low: 12/1000 inhabitants. There are no published reports on the effectiveness of chelation regimes. There is a growing number of patients surviving to adulthood but again no published age distribution.

Impression: Despite its increasing economic growth, the health services in Albania are lagging behind where haemoglobin disorders are concerned.

Azerbaijan. Azerbaijan is an energy-rich country, but GDP/capita is low compared to most other countries in this category. Over 5% of the population were living below the national poverty in 2023.

Epidemiology: There are around 1 per 5,000 of the population affected by haemoglobin disorders, amounting to a significant public health burden. Of these, 1000 are TDT, 350 NTDT, and 200 SCD.

Prevention: A programme of premarital screening has been mandated by law since 2015 including genetic counselling of at-risk couples and the offer of prenatal diagnosis. Since 2015, over 500,000 people have been tested, of which 3.7% have been found to be carriers of β-thalassaemia.19 Prenatal diagnosis is available and by 2024, 271 foetal samples were analysed.20 Around 20% of marriages are consanguineous (previously reported coefficient was 0.0103), while recent urbanisation may have reduced this practice. Birth prevalence is generally falling.

Clinical services: All patients in the country are treated in one centre in Baku, the Republican Thalassaemia Centre, which means that clinical and scientific expertise are concentrated and provided for the benefit of patients, even though travelling may cause financial and other difficulties for several patients. Blood for transfusion is provided by one centre, the Institute of Haematology and Transfusion Medicine. Measurement of cardiac and liver iron by MRI is still not available, and so those that can afford it, travel to other countries, mainly Türkiye, for their annual tests.

Impression: The service has not yet reached optimal quality in case management but has the potential to do so if service improvement becomes a policy.

Bulgaria. This is a Balkan country of south Europe, member of the EU since 2007. Bulgaria has low health expenditure per capita by EU standards (1258 USD). It is classified as a HIC, but health services have yet to reach the standards of its fellow members states. Out-of-pocket health spending is often necessary but to what extent this affects β-thalassaemia patients is uncertain.

Epidemiology: Carrier prevalence is mostly in specific regions, along the Black Sea coast and the south. No HbS reported in the indigenous population. There are 250-300 β-thalassaemia patients followed in the three main centres.

Prevention: It is not centrally organised and there are no records on birth prevalence. There is limited use of prenatal diagnosis.

Clinical services: Bulgaria has made considerable improvements in recent years in clinical management of β-thalassaemia. Blood donations/1000 of the population reached 27.7 in 2024, which is low by EU standards. Donations are roughly 85-95% family/replacement donations. In a study from a single centre, 19.5% of TDT patients had normal liver MRI in 2011; in 2014 these rose to 37%.21 This is an indication of improving standards of care.

Impression: Bulgaria with an improving national economy is expected to improve in both care delivery and prevention.

Cyprus. This is a politically divided island. The total populations is 1.38 million, while roughly 1 million live on the side controlled by the Republic and 380,000 live on the Türkiye occupied region. There are separate healthcare systems on the two sides of the island but as far as β-thalassaemia is concerned the systems fully support both treatment and prevention, and practices are similar.

Epidemiology: The carrier rates are similar in both the communities of the island. In the absence of prevention, annual expected β-thalassaemia births are 4.9 per 1000 live births, one of the highest rates globally.

Prevention: Cyprus was one of the first countries to respond to the high burden of β-thalassaemia, with programmes dating back to the early 1970s. Premarital screening which was mandated by the Orthodox Church is now less relevant since civil weddings and cohabitation are increasing. According to the national registry, there have been 31 β-thalassaemia homozygote and 10 SCD births between 2020 and 2024, while in the 1980s, affected births were almost zero. This change probably stems from the conversion of a fatal disease of childhood to a chronic disease of adulthood, and the prospect of novel therapies, including curative approaches which are now a reality. The objective documentation of improved survival has resulted in the birth of new patients to couples who have been counselled but chose to proceed with the pregnancy because of the more optimistic prognosis.

Clinical services: Cyprus has one of the highest rates of voluntary blood donors in the world. Donations are 100% voluntary and non-remunerated. For the majority of patients, pretransfusion haemoglobin level is maintained at the recommended threshold of 10 g/dL or higher. All means to monitor and treat iron overload are available. Among 652 patients with β-thalassaemia, only 72 (11%) are aged <18 years (10.6% with TDT and 14.3% with NTDT). The mean age of patients is 42.3 years. The aging population of patients reflects the quality of services offered. In addition, there are 60 β-thalassaemia patients who have undergone haematopoietic stem cell transplantation (HSCT) over the years.8,22

Impression: The policies initiated in Cyprus five decades ago have paid dividends since apart from a reduced birth prevalence, the patients have achieved prolonged survival and a good quality of life.

Greece. Greece is a Mediterranean country of almost 10 million people. Despite health coverage, some specialist visits are paid for out-of-pocket.

Epidemiology: The geographical distribution is not homogeneous, and pockets of high prevalence have long been recognised.

Prevention: With a carrier rate of 8% for β-thalassaemia, Greece was one of the first countries to introduce a comprehensive prevention programme in the 1970s. Premarital screening leading to prenatal diagnosis were accepted by the population.23 Over 30 years, prevention reduced expected affected births from about 800-900/year to only 50/year, while at the same time, significantly increasing survival rates and quality of life.24

Clinical services: In a recent multicentre study, the average pretransfusion haemoglobin level was 9.9 g/dL.25 Around 20-25% of the donated blood units used annually in the hospitals are for TDT patients. Serum ferritin levels were below 1000 ng/mL (mean 549.3 ng/mL) and liver iron concentration (LIC) was at low levels (median 2.2 mg/g dry liver weight) in the majority of patients in recent reports.25 In a cohort of about 200 patients from the national registry, the median (interquartile range) age at enrolment was 45.7 (40.2-50.5) years, with 49 (24.4%) patients aged 18-40 years and the remaining 152 (75.6%) aged >40 years.25 Total costs of treatment were 32,064 EUR/year for the whole period of 2009-2011 and reached 32,564 EUR in 201126, while the annual cost of SCD in steady state was estimated to be 21,152,340 EUR.27 Patients also benefit from disease-specific social benefits, which include the annual provision of 22 leave days for patients for blood transfusions, the coverage of transport expenses, the right to full retirement after 15 years of employment, and facilitated access (by quotas) to higher education and employment. People with a 67% disability can claim a disability pension after 5 years of employment and are entitled to tax exemption for the purchase of a car.

Impression: Greece has indicatives of good clinical management, reflected in long patient survival and quality of life.

Italy. Italy is a country of almost 59 million people. The health system in Italy boasts excellent results in all areas. Epidemiology: The prevalence of thalassaemia carriers is higher in the southern areas and in Sardinia where 10.3% of school children were heterozygotes for β-thalassaemia.28,29 The distribution of HbS was once regional (mainly Sicily) but is now frequent in most Italian centres. In a large, nation-wide, epidemiologic survey (December 2019) a total of 9,517 patients with haemoglobinopathies were identified, including 5,205 TDT (54.7%), 1,964 NTDT (20.6%), and 2,348 SCD (24.7%).30 In addition, Italy is a common destination for migrants. Indeed, of a total immigrant population of 6,274,000, it is estimated that 3,622,000 (57.7%) are from countries with high prevalence of haemoglobin disorders; 91,994 (2.5%) are expected to have β-thalassaemia genes and 103,966 (2.9%) HbS.

Prevention: The tradition for screening for β-thalassaemia carriers was introduced in the 1950s in Italy by the pioneers Silvestroni and Bianco.31 It eventually became routine in some regions, mainly in Sardinia32 and spread to most regions throughout the 1980s. In Sicily, a reduction of about 85% of affected births was recorded.33 In recent reports, improved medical treatments leading to increased survival of patients and cultural factors, are leading to increased acceptance of affected pregnancies.34

Clinical services: Blood donations in Italy are 100% derived from voluntary non-remunerated donations and over 40/1000 of the population are donors. The Italian National Blood Centre (CNS) ensures national self-sufficiency, achieving the highest levels of safety and complying with European legislation in terms of quality. In addition, the CNS manages the National Registry of Thalassemia and other Haemoglobinopathies. The effectiveness of iron overload monitoring and chelation is reflected through data from large patient cohorts. In one study of 3986 patients treated at 36 centres (2021), 19% were found to have severe iron overload, while in 74%, the LIC was <7.5 mg/g. The cardiac T2* was >20 ms in 85%.29 In another study of seven major centres, the median serum ferritin level was 982 ng/mL (48.4% had a level >1000 ng/mL).7 Such results indicate that while some reference centres in Italy have optimal control of iron overload, the overall national performance could still be improved. The cost of treatment for patients with TDT, per patient per year, was 31,883 EUR in 2017.35 The age distribution of β-thalassaemia patients is nearing that of the general population, with most adults being in their 40-50s; while for SCD the age distribution is younger as the patient population is largely formed of young immigrants.30

Impression: Italy has pioneered prevention and clinical practices concerning β-thalassaemia and SCD. It boasts several centres of excellence with considerable research output. More recently, it was one of the first European countries to introduce gene therapy.

Malta. Malta and Gozo are small Mediterranean islands with a population of over 500,000. There is a high-quality, tax-funded national health system that is free at the point of delivery for residents.

Epidemiology: There are 33 patients being treated in Malta with haemoglobin disorders. Of these, 26 have TDT, 3 have NTDT, and 4 have SCD.36

Prevention: There is a programme of antenatal screening of pregnant women and their partners. However, prenatal diagnosis is not practiced.

Clinical services: Data on management and outcomes are limited. There are adequacy and safety of blood donation for haemoglobin disorders (5% of the population donate blood annually), and good access to iron monitoring and chelation.

Impression: Although detailed information on current clinical care and outcomes is not available, previous communications with the University of Malta’s thalassaemia clinic indicated a high standard of care for the 33 patients.

North Macedonia. A small South Balkan country which was part of Yugoslavia, now gradually developing economically. It has a mixed population of southern Slavs (58%), Albanians (26%), and other minorities. The healthcare system is funded mainly through public health insurance, but is still under development.

Epidemiology: Even though β-thalassaemia carrier rate was reported to be 2.6%, the total patient population is not recorded (from patient reports, only 25 cases of β-thalassaemia are confirmed).

Prevention: There is no national β-thalassaemia prevention programme.

Clinical services: No published reports are available, although patient feedback suggests that the quality of clinical care may be suboptimal.

Impression: Haemoglobin disorders services remain underdeveloped, with limited epidemiological data, no national prevention programme, and concerns regarding the quality of clinical care, highlighting the need for a coordinated national strategy.

Tajikistan. This is a Central Asian Republic with an ethnically diverse population of over 10 million. It is a LMIC with low health expenditure per capita (85.15 USD), poor UHC (index 72) and relatively low HDI (0.691).

Epidemiology: The carrier rate for β-thalassaemia is said to be 5% overall but may be as high as 7-10% in some regions.37 Based on these estimates, it is calculated that there could be 0.625/1000 annual live births. Affected patient numbers are unknown.

Prevention: There is no national β-thalassaemia prevention programme.

Clinical services: No published reports are available.

Conclusion: The lack of contact with patients and physicians to gather information is a matter of concern and TIF is making efforts to correct this.

Türkiye. The Republic of Türkiye is a large eastern Mediterranean country of over 87 million people. It is classified as an UMIC. The healthcare system includes universal public coverage with a large, private sector.

Epidemiology: There are large regional variations in the prevalence of haemoglobin disorders. Furthermore, the country also hosts over 3.7 million Syrian refugees and smaller numbers of migrants from Iraq, Iran, and other countries with significant prevalence of haemoglobin disorders. This is already recognised among the Syrian group, where the Turkish government has developed and supported services for patients.38 According to 2017 national registry data, 72% of the 2,046 patients treated across 27 thalassaemia centres were under 20 years of age.39

Prevention: Prevention programs were initially concentrated in 33 provinces where prevalence is highest. The number of affected newborns reported annually was reduced from 272 in 2002 to 25 in 2010, indicating that prevention through premarital screening was considerably successful (90%). The rate of consanguineous marriages is high (21%) in communities of eastern Türkiye that have a high prevalence of β-thalassaemia.40,41

Clinical services: Blood transfusion services in Turkey are primarily managed by the Turkish Red Crescent (Türk Kızılay) which is responsible for adequacy and safety. A recent survey identified disparities in transfusion practices and transfusion-service laboratory infrastructure for patients with haemoglobinopathies across Türkiye.42 In another recent study, the proportion of patients with safe LIC values (<7 mg/g) increased from 57% to 77%, while those with safe cardiac T2* values (>20 ms) increased from 72% to 86% between 2006 and 2019.43 According to patient association reports, the quality and effectiveness of care vary across centres, with suboptimal management contributing to poorer outcomes in some centres. Direct medical care costs were estimated in a study published in 2017. For patients with TDT, the total annual direct costs per patient were 14,360 USD, while for patients with NTDT the cost was lower at 9,286 USD.44

Impression: A large country like Türkiye, with a significant number of affected patients, offers free care for haemoglobinopathy patients. In addition, it has initiated in all high-prevalence regions and beyond, a prevention programme which has succeeded in reducing birth prevalence. In reference and academic centres, management is exemplary, but in such a large country, peripheral centres are in some cases lagging behind although quality of care is generally improving.

Uzbekistan. The current population of Uzbekistan is over 35 million. It is a LMIC with a low GDP/capita of which health care takes up <5%.

Epidemiology: In one study based on a survey of villages, the mean β-thalassaemia gene frequency was 0.0159, corresponding to an estimated carrier prevalence of 3.18% in the population.45 Approximately 500 patients with thalassaemia have been reported, with an estimated 111 new affected births expected annually.46

Prevention: There are no screening programmes in Uzbekistan.

Clinical services: Blood donations currently stand at approximately 10 per 1,000 population. Until 2015, around 40% of donations were from family replacement donors, although more recent data are unavailable. Iron chelation therapy reaches only 18% of patients, and no additional clinical data are available.46

Impression: There are still inadequate contact and inadequate information from this country.

Table 3 summarises clinical outcome indicators from the 11 countries.

Table 3. Clinical outcome indicators in high-prevalence countries.

CountryPreventionβ-thal patientsMean age (years)SCD patientsBlood serviceMean pretransfusion Hb (g/dL)Donations/1000 populationIron chelatorsMRI for LICNational registryAnnual cost of care
AlbaniaNo national programme, cascade screening356NA174Nationally coordinated≥10123 available freeUnavailableNoNA
AzerbaijanMandated since 2015, premarital1000 TDT
350 NTDT
NA200Provided at one centerNA12-133 available, periodic shortagesUnavailable, sought from neighboring countriesNoNA
BulgariaNo centralisation250-300NA0Nationally coordinatedNA27.7 (85-95% family)3 available freeAvailable freeNoNA
CyprusOngoing since 1972598 TDT
54 NTDT
~4290Nationally coordinated≥1058.63 available freeAvailable freeYesNA
GreeceOngoing since 19702099 TDT
873 NTDT
40-501060Decentralised, hospital-based system1052.63 available freeAvailable freeYes32,564 EUR for TDT in 2011
21,152,340 EUR for SCD in 2021
ItalyOngoing since 19805205 TDT
1964 NTDT
40-502348Nationally coordinated)9-10.5403 available freeAvailable freeYes31,883 EUR for TDT in 2017
MaltaAntenatal screening26 TDT
3 NTDT
NA4Nationally coordinatedNA36.43 available freeNANoNA
North MacedoniaNo national programme25NANAAvailableNANANANANANA
TajikistanNo national programmeNANANAAvailableNANANANANANA
TürkiyePremarital in 33 provinces5500NA4300Managed by Turkish Red CrescentNA30-352 used by 96%AvailableYes14,360 USD for TDT
9,286 USD for NTDT in 2017
UzbekistanNo national programme~500NANAAvailableNANASuboptimal accessNANANA

Abbreviations: β-thal, β-thalassaemia; SCD, sickle cell disease (including HbSS and HbS/β-thalassaemia); Hb, haemoglobin; MRI, magnetic resonance imaging; LIC, liver iron concentration; TDT, transfusion-dependent β-thalassaemia; NTDT, non-transfusion-dependent β-thalassaemia; NA, data not available.

Low-prevalence countries with established past and recent migrations

Low prevalence among indigenous populations does not imply that haemoglobin disorders are of limited public health relevance, particularly in an era of large-scale migration. Three European countries, France, the United Kingdom (UK), and the Netherlands, have received migrants from high-prevalence regions for over a century, partly reflecting their historical colonial ties. Consequently, these countries now have established second- and third-generation immigrant populations originating from regions of high haemoglobinopathy prevalence, including Asia, Africa, the Caribbean, and the Middle East. As HIC with advanced healthcare infrastructure and universal health coverage, their health systems have progressively adapted over many years to address the needs of these populations.

The Afro-Caribbean origin of many migrants has contributed to a substantial population of patients with SCD. In France, there are more than 32,000 patients with SCD and approximately 800 with β-thalassaemia.47,48 In the UK, the national registry includes more than 15,000 patients with SCD and over 2,000 with β-thalassaemia.49 In the Netherlands, there are approximately 350 patients with β-thalassaemia, mainly of Mediterranean origin, and around 2,000 with SCD (approximately 11 per 100,000 population).50

In the UK, a substantial proportion of migrants have originated from the Indian subcontinent, a region with a high prevalence of haemoglobin disorders. Migration from the Caribbean and sub-Saharan Africa has also been considerable, contributing to increasing numbers of HbS carriers and patients with SCD. As these migration patterns have been established for many decades, clinical experience and services for haemoglobin disorders are generally well developed.

In France, approximately 13.8% of the population is of foreign origin. Nearly 45% of new immigrants originate from Africa, including North Africa (Algeria, Morocco, and Tunisia) and sub-Saharan Africa, particularly francophone West Africa, as well as the Caribbean. Migration from these regions increased substantially after the Second World War and has contributed to the predominance of SCD among haemoglobin disorders in France. In a cohort of 331 patients with TDT, the mean age was 26.1 years (range 1-88); 62% were aged over 18 years and 29% over 30 years, while the mean age at death was 52.5 years.51

In France, there is no specific national programme aimed at reducing births affected by haemoglobin disorders. Under French bioethics legislation, carrier testing for hereditary conditions, including haemoglobin disorders, is performed following prescription by a family doctor or gynaecologist, generally in the presence of a family history, a high risk associated with consanguinity, or another specific medical indication. A national neonatal screening programme is in place and primarily identifies SCD.52 Although organised carrier screening is not available, prenatal diagnosis is offered to at-risk couples at several centres across France. Termination of pregnancy is legally available at the mother’s request up to 16 weeks after the last menstrual period and may be performed later in pregnancy when two physicians certify that the foetus is affected by a severe condition.53 Haemoglobin disorders are not specifically included in the routine antenatal testing panel; however, a complete blood count is routinely performed and may identify findings suggestive of carrier status.

The situation differs in the UK, where a nationally coordinated prevention programme provides both antenatal and neonatal screening under the oversight of the National Screening Committee.54 Women undergo a complete blood count during the first trimester, and those with low red cell indices undergo further testing, guided by ethnic origin assessed through a Family Origin Questionnaire. If a haemoglobin disorder is identified, the partner is offered testing. Carrier couples receive genetic counselling and are offered prenatal diagnosis. During the ten-year period from 2007 to 2017, 3,941 prenatal diagnostic tests were reported in England, of which 964 identified an affected foetus.55 Overall, the programme has been successful within a highly multicultural population, although challenges remain in raising awareness and effectively reaching high-prevalence ethnic groups.56

In the Netherlands, the Health Council recommended a pilot programme for preconception carrier screening, although this has not been implemented.57 In the absence of a national policy, some midwifery practices in areas with relatively large immigrant populations offer screening on an ad-hoc basis. Pregnant women may therefore be offered ancestry-based carrier screening alongside standard information on prenatal screening for Down syndrome. When a carrier couple is identified during pregnancy, prenatal diagnosis (PND) can be offered. As almost 25% of the population of the Netherlands has a migration background, considerable cultural and religious diversity exists, contributing to differences in awareness, informed decision-making, uptake of screening, and attitudes towards termination of affected pregnancies.58

The clinical care infrastructure and quality of services in academic reference centres across these three countries generally support good outcomes for patients with β-thalassaemia and SCD. The main challenge lies in peripheral centres, where smaller patient numbers may limit clinical experience and expertise. This is illustrated by the UK registry,49 in which at least seven centres follow fewer than 20 patients with β-thalassaemia, including four with fewer than 10. Similarly, in France, fewer than 800 patients with β-thalassaemia are distributed across 57 centres.59 To address this challenge, networks have been established linking reference centres with peripheral centres, facilitating access to specialist expertise and supporting more consistent standards of care.

The level of blood provision and iron overload monitoring and management practices in these countries are exemplary and needs no further comment. The age distribution of patients in England indicates long survival.49 Nevertheless, there is also a paediatric population which may indicate poor uptake of the prevention programme but also a possible effect of recent migrations. The outcomes from both France and the Netherlands are similar and indicative of good clinical care in what is a rare condition affecting mainly the non-indigenous population.

Low-prevalence countries with increasing migration trends

Across a large part of Europe, haemoglobin disorders are rare among indigenous populations. However, recent migration during the first decades of the 21st century, driven by conflict as well as economic factors, has increased the number of patients with these conditions. Table 4 summarises key data from 14 countries in this category. Healthcare systems in many countries were initially unprepared for the complex and demanding needs of these patients. Although increasing awareness, provider education, and adaptation of services have improved care in some countries, the situation remains less clear in others.

Table 4. Haemoglobin disorders in low-prevalence European countries with increasing migration trends.

CountryEstimated β-thal
patients/100,000
population
Estimated SCD
patients/100,000
population
Expected β-thal
births/1000 LB
UHC
index
HDI
rank
Austria0.68NA0.0014840.930 v high
Belgium0.543.10.002860.951 v high
Croatia0.40.120.016760.889 v high
Denmark1.444.10850.962 v high
Germany0.746.20.0017870.959 v high
Ireland0.4410.00820.949 v high
KazakhstanNANA0.025830.837 v high
MontenegroNANA0.036700.862 v high
NorwayNANANA890.970 v high
Portugal0.377.40.051830.890 v high
RussiaNANA0.00018810.832 v high
SerbiaNANA0.036730.833 v high
Sweden6.66.30.0026850.959 v high
Switzerland0.812.50.004870.970 v high

Abbreviations: β-thal, β-thalassaemia; SCD, sickle cell disease (including HbSS and HbS/β-thalassaemia); LB, live annual births; NA, data not available; UHC, universal health coverage; HDI, human development index.

Only Sweden and Denmark have established national registries for haemoglobin disorders. In Norway, more than 2,000 individuals with β-thalassaemia and over 350 with SCD have been reported among the immigrant population, although these figures include carriers (based on a 2022 presentation by RE Borgersen, Oslo University Hospital).

With regard to prevention, most of these countries have limited systematic screening policies for at-risk couples, migrants, refugees, or asylum seekers. In Denmark, for example, screening in early pregnancy is guided by ethnic background.60,61 When carrier status, thalassaemia, or SCD is identified, screening may also be offered to siblings and parents. Awareness of haemoglobin disorders is increasing, and many carriers are identified during pregnancy. Prenatal diagnosis and preimplantation genetic diagnosis are available, while genetic counselling, although limited, can be accessed through university hospitals.

Patients with haemoglobin disorders are generally treated at their local hospitals and, in some countries, are also reviewed periodically at regional reference centres. However, access to state-of-the-art treatment and comprehensive multidisciplinary care remains inconsistent, largely because of limited coordination between services and insufficient expertise in these relatively rare disorders.

In HIC, blood transfusion services generally provide adequate and safe blood supplies, and iron chelation therapy is fully covered by healthcare systems. In lower-resource countries, deficiencies are likely to persist, although published data are scarce. Most European countries have a high HDI and sufficiently comprehensive UHC to support patients with β-thalassaemia. Nevertheless, the rarity of these disorders in many countries, together with limited professional expertise and fragmented services, can impede delivery of the coordinated, multidisciplinary care that these patients require.

Discussion

The WHO Regional Office for Europe (WHO/Europe) serves a region comprising 53 Member States. Of these, 11 fell under TIF’s definition of high prevalence, 3 were considered low-prevalence countries but with a unique and long-established impact of migrations from high-prevalence regions, and 14 were considered to be of low prevalence but with increasing trends due to recent migration. For the remaining 25 countries, we considered the available information mostly inadequate to allow any comments.

Rarity poses a major challenge to health services when conditions require complex management modalities, and this has prompted the European Commission to promote policies aimed at addressing service deficiencies arising from limited expertise and inadequate planning. There is a lack of experience and a need for greater education of health professionals about haemoglobinopathies. Among the policy initiatives was the creation of European Reference Networks (ERNs), which aim to pool experience and expertise. EuroBloodNet is the network that includes rare anaemias, including thalassaemia and SCD. As a result, the state of services for these conditions is being studied and collaborations are being developed across 27 participating Member States.62 For the rest of the continent, there are limited policies, if any, to support haemoglobinopathies in either prevention or case management, and substandard patient care therefore remains common.

In the 11 countries of high prevalence, services are of high quality in only five (Bulgaria, Cyprus, Greece, Italy, and Malta), based on outcome measures, particularly survival. While quality improvement is expected in all countries, greater efforts are needed in the remaining six to recognise unmet needs and address inequalities.

Service development needs are more complex in countries where these conditions were historically rare but are increasingly demanding attention as recent population shifts increase patient numbers. One major challenge in this group of countries is the lack of prevalence data and information on the geographical distribution of patients, since national registries exist in only a few countries. Consequently, service planning is not based on a solid understanding of patient needs. A major recommendation is therefore to develop registries and databases and make them interoperable, at least across the EU. Cross-border collaborations are also expected to develop so that expertise can reach every patient.

Rough estimates based on expert opinion, local association data, and registries indicate that, across the 53 European countries, the number of patients with β-thalassaemia syndromes is at least 26,000, while approximately 72,000 have SCD. These figures are probably underestimates in the absence of accurate data collection and are likely to change annually as population flows and new births, in the absence of prevention, add new affected patients. Patients are unevenly distributed but still constitute an important disease burden when the demand for all clinical and preventive services is considered.63

Estimating patient numbers is challenging, as they change from year to year with population flows, particularly from high-prevalence countries. In addition, several other considerations affect service delivery. These include language and communication difficulties, culture and religion, legal status, and access to health services; such factors add to the challenges associated with rarity and its inherent barriers to quality care. Many migrants, especially recent arrivals, face what has been termed ‘therapeutic remoteness’64; this refers to being remote from, or unable to access or benefit from, quality care as well as social support. The concept of remoteness and lack of access to expertise underpins the development of the rare disease networks described above: a hub-and-spoke model in which expert centres support peripheral centres so that patients may benefit from the expertise of a reference centre even while receiving care at a secondary facility. For migrants, the needs are even greater, since guidance may be required simply to access primary care, let alone specialist services. The formation of patient support associations can provide points of reference and guidance for migrants, as well as support for national patients where such associations exist. Central healthcare planning and support are, however, key to achieving a level of care that supports long-term survival. Political recognition of the public health burden of these lifelong conditions is needed, together with a national plan covering both prevention and quality improvement of services.

Concerning prevention of these disorders, it has been reported from both Cyprus and Italy that increasing numbers of carrier couples are choosing not to avoid affected pregnancies in view of improved survival and, possibly, the expectation of curative therapies. This attitude, together with the difficulties of reaching some migrant groups through awareness campaigns, is expected to result in increasing numbers of patients in the coming years.

An important next step is therefore to move from assessing the availability of services to systematically evaluating their quality and impact on patient outcomes. The presence of a prevention programme, specialist centre, or access to treatment does not necessarily ensure optimal implementation or equitable access. Common indicators that can be measured across countries, including age distribution and survival, adequacy of transfusion, control of iron overload, burden of disease-related complications, and access to multidisciplinary and disease-modifying care, could provide a more objective basis for benchmarking services. Harmonisation of such indicators through national registries and European networks would allow countries to identify gaps, monitor improvement over time, and learn from models that have successfully translated healthcare investment into improved patient outcomes.

Our work is not without limitations. The lack of data, and particularly of registries, restricts the ability to make comparisons. Expert opinion has contributed to some estimates. In addition, TIF relies on unpublished reports from many countries, even though these may be more up to date than published reports. All estimates are regarded as dynamic because migration may change figures from year to year. It is not possible to obtain adequate information from all countries in Europe. No formal statistical comparisons were undertaken because of the heterogeneity and incompleteness of the datasets.

Conclusion

Haemoglobin disorders represent an evolving public health challenge across Europe, shaped by historically high-prevalence populations, migration, and the increasing survival of affected patients. This assessment highlights substantial variation between countries in epidemiological surveillance, prevention strategies, organisation of specialist services, and indicators of quality of care. Priorities should include the development of reliable national registries, appropriate prevention strategies, and stronger reference networks and shared-care models to ensure that specialist expertise reaches patients irrespective of where they live. Particular attention is also needed to educate and guide migrant populations regarding haemoglobin disorders, available services, their rights, and pathways to accessing care, alongside improved education of healthcare professionals. Affected communities should be better informed about carrier identification and the availability of premarital, preconception, and antenatal screening and diagnostic options. Collectively, these measures should support a more coordinated and equitable European response, ensuring that advances in prevention and treatment translate into improved survival and quality of life for all patients.

Declarations

Funding
None.
Disclosures
DF reports speaker honoraria or consultation fees from Abbott, AstraZeneca, Avanzanite, Bayer, Boehringer Ingelheim, Leo, Menarini, NordicPharma, Roche, and Zoll; and research grants from the European Union. AP reports consultancy fees from Vertex Pharmaceuticals and Novo Nordisk; and speaker honoraria from Bristol Myers Squibb (Celgene Corp), Chiesi, Lapidot, and Pharmaforte. PE reports honoraria for advisory board meetings, talks at conferences and webinars from Pfizer, Novo Nordisk, Fulcrum Therapeutics, Avanzanite, and Vertex Pharmaceuticals. KMM reports consultancy fees from Novartis, Bristol Myers Squibb (Celgene Corp), Agios Pharmaceuticals, CRISPR Therapeutics, Vifor Pharma, Pharmacosmos, Novo Nordisk, NewBridge Pharmaceuticals, Avanzanite, and Vertex Pharmaceuticals; and research funding from Agios Pharmaceuticals and Pharmacosmos. The remaining authors have no conflicts of interest to disclose.

References

  1. Collaborators GBDSCD. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599.
  2. Soteriades ES, Angastiniotis M, Economidou EC, Farmakis D, Avraam D, Eleftheriou A. The disease burden of beta-thalassaemia revisited. Hematology. 2025;30(1):2551450.
  3. Aydinok Y, Purushotham S, Yucel A, et al. Systematic literature review of the indirect costs and humanistic burden of beta-thalassemia. Ther Adv Hematol. 2024;15:20406207241270872.
  4. Cazzola M. Ineffective erythropoiesis and its treatment. Blood. 2022;139(16):2460-2470.
  5. Colombatti R, Jastaniah W, Makani J, Andemariam B. Sickle cell disease. Lancet. 2026;407(10533):1095-1111.
  6. Delicou S, Xydaki A, Kamposou V, et al. Epidemiological and comorbidity burden in transfusion-dependent patients with thalassemia and sickle cell disease in Greece. Ann Hematol. 2026;105(3):95.
  7. Forni GL, Gianesin B, Musallam KM, et al. Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years. Am J Hematol. 2023;98(3):381-387.
  8. Angastiniotis M, Christou S, Kolnakou A, et al. The Outcomes of Patients with Haemoglobin Disorders in Cyprus: A Joined Report of the Thalassaemia International Federation and the Nicosia and Paphos Thalassaemia Centres (State Health Services Organisation). . Thalassemia Rep. 2022;12(4):143-156.
  9. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151.
  10. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704-712.
  11. Mohd Yasin N, Chatzimatthaiou S, Perolla A, et al. Mapping Current and Emerging Laboratory Techniques for Haemoglobinopathy Carrier Detection and Prevention: A Narrative Review from the HELIOS Action. International journal of molecular sciences. 2026;27(9).
  12. Musallam KM, Lombard L, Kistler KD, et al. Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps. Am J Hematol. 2023;98(9):1436-1451.
  13. Modell B, Darlison M, Birgens H, et al. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest. 2007;67(1):39-69.
  14. Angastiniotis M, Vives Corrons JL, Soteriades ES, Eleftheriou A. The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders. ScientificWorldJournal. 2013;2013:727905.
  15. Aguilar Martinez P, Angastiniotis M, Eleftheriou A, et al. Haemoglobinopathies in Europe: health & migration policy perspectives. Orphanet J Rare Dis. 2014;9:97.
  16. Eleftheriou A, Angastiniotis M. Global Thalassaemia Review 2025. Nicosia, Cyprus: Thalassaemia International Federation; 2025.
  17. Kreka M, Kreka B, Nastas E, et al. On beta thalassemia mutations, laboratory findings and treatment of Albanian patients. AJNTS. 2022;54:129-138.
  18. Seferi I, Xhetani M, Face M, Burazeri G, Nastas E, Vyshka G. Frequency and specificity of red cell antibodies in thalassemia patients in Albania. Int J Lab Hematol. 2015;37(4):569-574.
  19. Asadov C, Alimirzoeva Z, Mammadova T, Abdulalimov E, Aliyeva G, Mikayilzadeh A. Thalassaemia Prevention Program in Azerbaijan: Preliminary Report [abstract]. 14th International Conference on Thalassaemia and Other Haemoglobinopathies & 16th TIF Conference for Patients and Parents: Thessaloniki, Greece. 2017.
  20. Mammadova T, Asadov C, Alimirzoyeva Z, Abdulalimov E, Aliyeva G. Update on Prevention of Hemoglobinopathies in Azerbaijan. Hemoglobin. 2024;48(5):353-356.
  21. Georgiev PG, Sapunarova KG, Goranova-Marinova VS, Goranov SE. Reduction of Liver Iron Load in Adult Patients with beta-Thalassemia Major Treated with Modern Chelation Modalities. Folia Med (Plovdiv). 2020;62(2):265-270.
  22. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91(9):1187-1192.
  23. Loukopoulos D. Haemoglobinopathies in Greece: prevention programme over the past 35 years. Indian J Med Res. 2011;134(4):572-576.
  24. Kattamis C. Efficacy of Prolonged Implementation of National Programs for Prevention and Treatment of β-Thalassemia Patients. The Greek Experience. J Hematol Transfus. 2017;5(2):1067.
  25. Kattamis A, Voskaridou E, Delicou S, et al. Real-world complication burden and disease management paradigms in transfusion-related beta-thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross-sectional study. EJHaem. 2023;4(3):569-581.
  26. Geitona M, Karagianni V, Kattamis A, et al. The Economic Burden of Treating Thalassemia In Greece. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17(7):A526.
  27. Tsolakidis V, Vlachaki E, Papaioannou M, et al. Total Annual Economic Burden of Patients with Sickle Cell Disease in Steady State in Greece. Hemoglobin. 2021;45(3):143-149.
  28. Cao A, Congiu R, Sollaino MC, et al. Thalassaemia and glucose-6-phosphate dehydrogenase screening in 13- to 14-year-old students of the Sardinian population: preliminary findings. Community Genet. 2008;11(3):121-128.
  29. Longo F, Corrieri P, Origa R, et al. Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfus. 2021;19(3):261-268.
  30. Gianesin B, Piel FB, Musallam KM, et al. Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study. Haematologica. 2025;110(5):1211-1216.
  31. Silvestroni E, Bianco I. Screening for microcytemia in Italy: analysis of data collected in the past 30 years. Am J Hum Genet. 1975;27(2):198-212.
  32. Cao A, Furbetta M, Galanello R, et al. Prevention of homozygous beta-thalassemia by carrier screening and prenatal diagnosis in Sardinia. Am J Hum Genet. 1981;33(4):592-605.
  33. Giambona A, Damiani G, Vinciguerra M, et al. Incidence of haemoglobinopathies in Sicily: the impact of screening and prenatal diagnosis. International journal of clinical practice. 2015;69(10):1129-1138.
  34. Voi V, Giordano N, Sciannameo V, et al. Changes in attitudes towards prenatal diagnosis for haemoglobinopathies: a 40-year retrospective observational study in Northern Italy. BMJ Open. 2025;15(12):e106796.
  35. Angelucci E, Antmen A, Losi S, Burrows N, Bartiromo C, Hu XH. Direct Medical Care Costs Associated with β-Thalassemia Care in Italy [abstract]. Blood. 2017;130(Suppl 1):3368.
  36. Garozzo G, Messina R, Manca P, Aquilina A. Transfusion in hemoglobinopathies and red blood cell alloimmunization: data from Sicily, Sardinia and Malta. Blood Transfus. 2024;22(2):111-121.
  37. Gar'kavtseva RF, Musnitskaia EN, Kaurov RA. [Population genetics aspects of the study of hemoglobinopathies in the population of the southern regions of the Uzbek and Tadzhik Soviet Republics]. Probl Gematol Pereliv Krovi. 1976;21(1):37-41.
  38. Yazal Erdem A, Demir Yenigurbuz F, Pekpak E, et al. Refugee children with beta-thalassemia in Turkey: Overview of demographic, socioeconomic, and medical characteristics. Pediatr Blood Cancer. 2019;66(5):e27636.
  39. Aydinok Y, Oymak Y, Atabay B, et al. A National Registry of Thalassemia in Turkey: Demographic and Disease Characteristics of Patients, Achievements, and Challenges in Prevention. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2018;35(1):12-18.
  40. Canatan D, Delibas S. Report on Ten Years' Experience of Premarital Hemoglobinopathy Screening at a Center in Antalya, Southern Turkey. Hemoglobin. 2016;40(4):273-276.
  41. Ozdemir S, Oruc MA, Yazicioglu B, Turkan S. Premarital hemoglobinopathy screening program results of a province in the Black Sea region of Turkey: three years' experience. Postgrad Med. 2023;135(8):818-823.
  42. Gurlek Gokcebay D, Andic N, Turkish Hemoglobinopathy Survey I, Flegel WA. Survey of Red Cell Transfusion Therapy and Immunohematology Services for Patients with Hemoglobinopathies in Turkiye. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2025;42(3):196-202.
  43. Bayraktaroglu S, Karadas N, Onen S, Karapinar DY, Aydinok Y. Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study. Ann Hematol. 2022;101(3):521-529.
  44. Antmen A, Angelucci E, Losi S, Burrows N, Bartiromo C, Hu XH. Direct Medical Care Cost Associated with β-Thalassemia Care in Turkey [abstract]. Blood. 2017;130(Suppl 1):2094.
  45. Asanov A, Revazov AA, Gar'kavtseva RF, Zaitseva VM, Solov'eva NN. [Medical genetic study of the population of Uzbekistan. V. The frequency of heterozygous beta-thalassemia in 4 kishlaks of Urgut District, Samarkand Province]. Genetika. 1978;14(12):2197-2204.
  46. Nabiyeva AJ, Xudoyberdiyeva MO. Molecular Epidemiology, Clinical Outcomes, and Policy Interventions for Beta-Thalassemia in Uzbekistan: A Nationwide Study. Am J Ped Med Health Sci. 2025;3(4):2993-2149.
  47. Leleu H, Arlet JB, Habibi A, et al. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database. PLoS One. 2021;16(7):e0253986.
  48. French National Registry of Thalassemia Patients (NaThalY). Available at: https://epidemiologie-france.aviesan.fr/en/epidemiology/records/registre-des-patients-thalassemiques-en-france-registre-qualifie (accessed JUly 2026).
  49. The UK National Haemoglobinopathy Register: A database of patients with red cell disorders. 2024 Annual Report. Available at: https://nhr.mdsas.com/ (accessed July 2026).
  50. Drahos J, Soares Peres F, Reimes N, et al. Clinical burden and healthcare resource utilization of patients with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia in The Netherlands. Curr Med Res Opin. 2025;41(9):1655-1664.
  51. Baldwin J, Udeze C, Li N, et al. Clinical burden and healthcare resource utilization associated with managing transfusion-dependent beta-thalassemia in France. Curr Med Res Opin. 2024;40(8):1289-1295.
  52. Cavazzana M, Stanislas A, Remus C, et al. [Evidence for the widespread use of neonatal screening for sickle cell disease]. Med Sci (Paris). 2018;34(4):309-311.
  53. Dommergues M, Mandelbrot L, Mahieu-Caputo D, Boudjema N, Durand-Zaleski I, foetale ICIG-Cdm. Termination of pregnancy following prenatal diagnosis in France: how severe are the foetal anomalies? Prenat Diagn. 2010;30(6):531-539.
  54. Bain BJ, Daniel Y, Henthorn J, et al. Significant haemoglobinopathies: A guideline for screening and diagnosis: A British Society for Haematology Guideline: A British Society for Haematology Guideline. Br J Haematol. 2023;201(6):1047-1065.
  55. Weil LG, Charlton MR, Coppinger C, Daniel Y, Streetly A. Sickle cell disease and thalassaemia antenatal screening programme in England over 10 years: a review from 2007/2008 to 2016/2017. J Clin Pathol. 2020;73(4):183-190.
  56. Boardman FK, Hale R. "I didn't take it too seriously because I'd just never heard of it": Experiential knowledge and genetic screening for thalassaemia in the UK. J Genet Couns. 2019;28(1):141-154.
  57. Holtkamp KCA, Lakeman P, Hader H, et al. Experiences of a High-Risk Population with Prenatal Hemoglobinopathy Carrier Screening in a Primary Care Setting: a Qualitative Study. J Genet Couns. 2018;27(3):635-646.
  58. van Vliet ME, Kerkhoffs JH, Harteveld CL, Houwink EJF. Hemoglobinopathy screening in primary care in the Netherlands: exploring the problems and needs of patients and general practitioners. Eur J Hum Genet. 2023;31(4):417-423.
  59. Thuret I, Pondarre C, Loundou A, et al. Complications and treatment of patients with beta-thalassemia in France: results of the National Registry. Haematologica. 2010;95(5):724-729.
  60. Glenthoj A, Helby J, Schmidt MC, Salih M, Petersen J. Coverage of antenatal haemoglobinopathy screening in the Capital Region of Denmark: a laboratory-based evaluation of screening implementation. Scand J Clin Lab Invest. 2026:1-10.
  61. Gravholt EAE, Jorgensen FS, Holm C, et al. Optimisation of the Danish national haemoglobinopathy screening programme - A prospective intervention study. EJHaem. 2025;6(3):e980.
  62. Manu Pereira MDM, Colombatti R, Alvarez F, et al. Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective. Lancet Haematol. 2023;10(8):e687-e694.
  63. Musallam KM, Cappellini MD, Porter JB, et al. TIF Guidelines for the Management of Transfusion-Dependent beta-Thalassemia. Hemasphere. 2025;9(3):e70095.
  64. Knoll EM. Adults with sickle-cells in a migration-driven rare disease setting: Therapeutic remoteness and graphic medicine in Austria. Soc Sci Med. 2026;388:118723.

Article information

Authors

  • Michael AngastiniotisThalassaemia International Federation (TIF), Nicosia, CyprusCorresponding author · [email protected]
  • Lily CannonThalassaemia International Federation (TIF), Nicosia, Cyprus
  • Dimitrios FarmakisDepartment of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
  • Antonio PigaUniversity of Turin, Turin, Italy
  • Perla EleftheriouDepartment of Haematology, University College London Hospital, London, United Kingdom
  • Khaled M. MusallamCenter for Research on Rare Blood Disorders (CR-RBD) and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; Department of Public Health & Epidemiology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates; Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA
  • Androulla EleftheriouThalassaemia International Federation (TIF), Nicosia, Cyprus

How to cite

Angastiniotis, M., Cannon, L., et al., 2026. A Multi-Source Assessment of The Current Status of Prevention and Clinical Services for Haemoglobin Disorders in Europe. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0607

Record

Journal
Medical Research Archives
Section
Research Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
99

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.